CN107375847A - 一种减肥药物、其制备方法及应用 - Google Patents
一种减肥药物、其制备方法及应用 Download PDFInfo
- Publication number
- CN107375847A CN107375847A CN201710692953.2A CN201710692953A CN107375847A CN 107375847 A CN107375847 A CN 107375847A CN 201710692953 A CN201710692953 A CN 201710692953A CN 107375847 A CN107375847 A CN 107375847A
- Authority
- CN
- China
- Prior art keywords
- parts
- prepared
- weight
- fat
- radix
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 76
- 238000002360 preparation method Methods 0.000 title claims abstract description 21
- 239000008187 granular material Substances 0.000 claims abstract description 37
- 229920001661 Chitosan Polymers 0.000 claims abstract description 19
- 235000009917 Crataegus X brevipes Nutrition 0.000 claims abstract description 19
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 claims abstract description 19
- 235000009685 Crataegus X maligna Nutrition 0.000 claims abstract description 19
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 claims abstract description 19
- 235000009486 Crataegus bullatus Nutrition 0.000 claims abstract description 19
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 claims abstract description 19
- 235000009682 Crataegus limnophila Nutrition 0.000 claims abstract description 19
- 235000004423 Crataegus monogyna Nutrition 0.000 claims abstract description 19
- 235000002313 Crataegus paludosa Nutrition 0.000 claims abstract description 19
- 235000009840 Crataegus x incaedua Nutrition 0.000 claims abstract description 19
- 239000009636 Huang Qi Substances 0.000 claims abstract description 19
- 240000002853 Nelumbo nucifera Species 0.000 claims abstract description 19
- 235000006508 Nelumbo nucifera Nutrition 0.000 claims abstract description 19
- 235000006510 Nelumbo pentapetala Nutrition 0.000 claims abstract description 19
- 244000163122 Curcuma domestica Species 0.000 claims abstract description 17
- 235000003392 Curcuma domestica Nutrition 0.000 claims abstract description 17
- 235000003373 curcuma longa Nutrition 0.000 claims abstract description 17
- 235000013976 turmeric Nutrition 0.000 claims abstract description 17
- 235000010447 xylitol Nutrition 0.000 claims abstract description 15
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims abstract description 13
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims abstract description 13
- 239000000811 xylitol Substances 0.000 claims abstract description 13
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims abstract description 13
- 229960002675 xylitol Drugs 0.000 claims abstract description 13
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims abstract description 12
- 229930195725 Mannitol Natural products 0.000 claims abstract description 12
- 239000000594 mannitol Substances 0.000 claims abstract description 12
- 235000010355 mannitol Nutrition 0.000 claims abstract description 12
- 239000000203 mixture Substances 0.000 claims abstract description 10
- 239000002775 capsule Substances 0.000 claims abstract description 8
- 238000009472 formulation Methods 0.000 claims abstract description 5
- 239000003826 tablet Substances 0.000 claims abstract description 5
- 239000006072 paste Substances 0.000 claims abstract description 3
- 239000000284 extract Substances 0.000 claims description 25
- 229940079593 drug Drugs 0.000 claims description 21
- 241001092040 Crataegus Species 0.000 claims description 18
- 239000003795 chemical substances by application Substances 0.000 claims description 11
- 239000000843 powder Substances 0.000 claims description 11
- 229910001385 heavy metal Inorganic materials 0.000 claims description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 9
- 238000004140 cleaning Methods 0.000 claims description 9
- 239000011347 resin Substances 0.000 claims description 7
- 229920005989 resin Polymers 0.000 claims description 7
- 238000001179 sorption measurement Methods 0.000 claims description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 6
- 239000002801 charged material Substances 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 239000003643 water by type Substances 0.000 claims description 6
- 235000009508 confectionery Nutrition 0.000 claims description 5
- 238000004108 freeze drying Methods 0.000 claims description 5
- 238000005469 granulation Methods 0.000 claims description 5
- 230000003179 granulation Effects 0.000 claims description 5
- 239000000463 material Substances 0.000 claims description 5
- 235000020985 whole grains Nutrition 0.000 claims description 5
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 claims description 4
- 239000003456 ion exchange resin Substances 0.000 claims description 4
- 229920003303 ion-exchange polymer Polymers 0.000 claims description 4
- 239000002245 particle Substances 0.000 claims description 4
- 238000000605 extraction Methods 0.000 claims description 3
- 239000000706 filtrate Substances 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 238000004094 preconcentration Methods 0.000 claims description 3
- 238000003756 stirring Methods 0.000 claims description 3
- 239000006228 supernatant Substances 0.000 claims description 3
- 150000005846 sugar alcohols Chemical class 0.000 claims description 2
- 239000002023 wood Substances 0.000 claims description 2
- 238000000034 method Methods 0.000 abstract description 18
- 230000000694 effects Effects 0.000 abstract description 12
- 206010012735 Diarrhoea Diseases 0.000 abstract description 9
- 238000009825 accumulation Methods 0.000 abstract description 4
- 230000002093 peripheral effect Effects 0.000 abstract description 3
- 206010000087 Abdominal pain upper Diseases 0.000 abstract description 2
- 230000013872 defecation Effects 0.000 abstract description 2
- 230000037406 food intake Effects 0.000 abstract description 2
- 235000012631 food intake Nutrition 0.000 abstract description 2
- 230000000968 intestinal effect Effects 0.000 abstract description 2
- 210000000936 intestine Anatomy 0.000 abstract description 2
- 230000008855 peristalsis Effects 0.000 abstract description 2
- 210000001835 viscera Anatomy 0.000 abstract description 2
- 230000004580 weight loss Effects 0.000 abstract description 2
- 240000000171 Crataegus monogyna Species 0.000 abstract 1
- 238000000354 decomposition reaction Methods 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 35
- 235000013305 food Nutrition 0.000 description 18
- 241000700159 Rattus Species 0.000 description 15
- 230000037396 body weight Effects 0.000 description 13
- 206010062717 Increased upper airway secretion Diseases 0.000 description 11
- 208000026435 phlegm Diseases 0.000 description 11
- 208000008589 Obesity Diseases 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 235000020824 obesity Nutrition 0.000 description 7
- 239000002253 acid Substances 0.000 description 6
- 230000017531 blood circulation Effects 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 206010033307 Overweight Diseases 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000003304 gavage Methods 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 239000000575 pesticide Substances 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 235000021251 pulses Nutrition 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 229910052785 arsenic Inorganic materials 0.000 description 3
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 description 3
- 229910052793 cadmium Inorganic materials 0.000 description 3
- BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 description 3
- 208000029078 coronary artery disease Diseases 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 235000013312 flour Nutrition 0.000 description 3
- 235000013402 health food Nutrition 0.000 description 3
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 3
- 229910052753 mercury Inorganic materials 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 235000021590 normal diet Nutrition 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 238000004506 ultrasonic cleaning Methods 0.000 description 3
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 240000001341 Reynoutria japonica Species 0.000 description 2
- 235000018167 Reynoutria japonica Nutrition 0.000 description 2
- 244000299790 Rheum rhabarbarum Species 0.000 description 2
- 235000009411 Rheum rhabarbarum Nutrition 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- 238000001467 acupuncture Methods 0.000 description 2
- JLYXXMFPNIAWKQ-SHFUYGGZSA-N alpha-hexachlorocyclohexane Chemical compound Cl[C@H]1[C@H](Cl)[C@@H](Cl)[C@H](Cl)[C@H](Cl)[C@H]1Cl JLYXXMFPNIAWKQ-SHFUYGGZSA-N 0.000 description 2
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- NYPJDWWKZLNGGM-UHFFFAOYSA-N fenvalerate Chemical compound C=1C=C(Cl)C=CC=1C(C(C)C)C(=O)OC(C#N)C(C=1)=CC=CC=1OC1=CC=CC=C1 NYPJDWWKZLNGGM-UHFFFAOYSA-N 0.000 description 2
- FRCCEHPWNOQAEU-UHFFFAOYSA-N heptachlor Chemical compound ClC1=C(Cl)C2(Cl)C3C=CC(Cl)C3C1(Cl)C2(Cl)Cl FRCCEHPWNOQAEU-UHFFFAOYSA-N 0.000 description 2
- CKAPSXZOOQJIBF-UHFFFAOYSA-N hexachlorobenzene Chemical compound ClC1=C(Cl)C(Cl)=C(Cl)C(Cl)=C1Cl CKAPSXZOOQJIBF-UHFFFAOYSA-N 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical class [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 229910021642 ultra pure water Inorganic materials 0.000 description 2
- 239000012498 ultrapure water Substances 0.000 description 2
- QBUKAFSEUHGMMX-MTJSOVHGSA-N (5z)-5-[[3-(1-hydroxyethyl)thiophen-2-yl]methylidene]-10-methoxy-2,2,4-trimethyl-1h-chromeno[3,4-f]quinolin-9-ol Chemical group C1=CC=2NC(C)(C)C=C(C)C=2C2=C1C=1C(OC)=C(O)C=CC=1O\C2=C/C=1SC=CC=1C(C)O QBUKAFSEUHGMMX-MTJSOVHGSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 239000005946 Cypermethrin Substances 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- YVGGHNCTFXOJCH-UHFFFAOYSA-N DDT Chemical compound C1=CC(Cl)=CC=C1C(C(Cl)(Cl)Cl)C1=CC=C(Cl)C=C1 YVGGHNCTFXOJCH-UHFFFAOYSA-N 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 235000019733 Fish meal Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 208000000913 Kidney Calculi Diseases 0.000 description 1
- 208000037093 Menstruation Disturbances Diseases 0.000 description 1
- 206010027339 Menstruation irregular Diseases 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010029148 Nephrolithiasis Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000031964 Other metabolic disease Diseases 0.000 description 1
- 244000131316 Panax pseudoginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 244000273256 Phragmites communis Species 0.000 description 1
- 235000014676 Phragmites communis Nutrition 0.000 description 1
- 241001522129 Pinellia Species 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 240000004980 Rheum officinale Species 0.000 description 1
- 235000008081 Rheum officinale Nutrition 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 240000006394 Sorghum bicolor Species 0.000 description 1
- 235000011684 Sorghum saccharatum Nutrition 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 241000256856 Vespidae Species 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000002058 anti-hyperglycaemic effect Effects 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- 239000002374 bone meal Substances 0.000 description 1
- 229940036811 bone meal Drugs 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000000799 cathartic agent Substances 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 201000001352 cholecystitis Diseases 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- FRCCEHPWNOQAEU-LDSHLKOWSA-N cis-heptachlordane Chemical compound ClC1=C(Cl)[C@@]2(Cl)[C@H]3C=C[C@H](Cl)[C@H]3[C@]1(Cl)C2(Cl)Cl FRCCEHPWNOQAEU-LDSHLKOWSA-N 0.000 description 1
- 239000003026 cod liver oil Substances 0.000 description 1
- 235000012716 cod liver oil Nutrition 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- KAATUXNTWXVJKI-UHFFFAOYSA-N cypermethrin Chemical compound CC1(C)C(C=C(Cl)Cl)C1C(=O)OC(C#N)C1=CC=CC(OC=2C=CC=CC=2)=C1 KAATUXNTWXVJKI-UHFFFAOYSA-N 0.000 description 1
- 229960005424 cypermethrin Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 239000003866 digestant Substances 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000000918 epididymis Anatomy 0.000 description 1
- 201000010063 epididymitis Diseases 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 239000003337 fertilizer Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000004467 fishmeal Substances 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 208000001130 gallstones Diseases 0.000 description 1
- JLYXXMFPNIAWKQ-GNIYUCBRSA-N gamma-hexachlorocyclohexane Chemical compound Cl[C@H]1[C@H](Cl)[C@@H](Cl)[C@@H](Cl)[C@H](Cl)[C@H]1Cl JLYXXMFPNIAWKQ-GNIYUCBRSA-N 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- MEBQXILRKZHVCX-UHFFFAOYSA-N methidathion Chemical compound COC1=NN(CSP(=S)(OC)OC)C(=O)S1 MEBQXILRKZHVCX-UHFFFAOYSA-N 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 208000001022 morbid obesity Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 238000006396 nitration reaction Methods 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- LKPLKUMXSAEKID-UHFFFAOYSA-N pentachloronitrobenzene Chemical compound [O-][N+](=O)C1=C(Cl)C(Cl)=C(Cl)C(Cl)=C1Cl LKPLKUMXSAEKID-UHFFFAOYSA-N 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000000384 rearing effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 230000036186 satiety Effects 0.000 description 1
- 235000019627 satiety Nutrition 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- JAJWGJBVLPIOOH-IZYKLYLVSA-M sodium taurocholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 JAJWGJBVLPIOOH-IZYKLYLVSA-M 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 235000015099 wheat brans Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/884—Alismataceae (Water-plantain family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/62—Nymphaeaceae (Water-lily family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/708—Rheum (rhubarb)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/734—Crataegus (hawthorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/13—Preparation or pretreatment of starting material involving cleaning, e.g. washing or peeling
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/55—Liquid-liquid separation; Phase separation
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种减肥药物、其制备方法及应用,属于减肥药物技术领域。所述的减肥药物,是由以下组分按重量份数制备而成:泽泻25‑35份、黄芪20‑40份、山楂15‑25份、熟大黄10‑20份、荷叶10‑20份、姜黄10‑20份、壳聚糖5‑12份、甘露醇16‑19份和木糖醇19‑21份。所述的减肥药物的剂型可为汤剂、膏剂、颗粒剂、胶囊剂或片剂。本发明的减肥药物减肥过程舒缓,促进肠道蠕动及排便,不会产生腹泻腹痛;减少食物摄入量,促进肠道脂肪的分解,抑制内脏周围脂肪的积聚和体重增加,减肥效果明显。
Description
技术领域
本发明属于减肥药物技术领域,具体涉及一种减肥药物、其制备方法及应用。
背景技术
随着经济社会的发展,生活水平的提高,肥胖逐渐成为人们的首要健康问题。不仅影响人们的工作学习生活,而且还会引起其他高发代谢性疾病,如冠心病、糖尿病、高血压、高血脂等,降低生存质量,缩短机体寿命。首先是与死亡的关系,研究表明,重度肥胖者寿命明显缩短,轻、中度的肥胖也伴随死亡率的明显上升,并与早年死亡率升高有关。成年期肥胖是老年期死亡的强有力的预测因子。其次,肥胖者发生多种疾病的机会增加。医学研究证实,肥胖是冠心病、高血压、糖尿病、脑卒中发生的独立危险因素。肥胖者患冠心病的危险性为正常人的2-3倍,体重每增加1Kg,患心血管病的危险性增加3.1%。肥胖者发生2型糖尿病的危险性是正常人3倍。肥胖者患脂肪肝、胆结石、胆囊炎、痛风、不孕症、关节炎、肿瘤、呼吸睡眠暂停综合征、肥胖相关性肾小球病和月经不调的机率明显增加。第三,肥胖不仅使人早亡、易得病,而且使活着的人生活质量严重下降和恶化。正因肥胖带来如此多的问题,如何科学的预防和治疗肥胖成为大家关注的焦点。不引起腹泻,减轻体重而不降低体力是减肥效果的评价原则。常见的减肥方法有药物治疗、针灸疗法、运动减肥、手术减肥等方法,但药物治疗虽见效快但副作用亦明显,针灸疗法、手术减肥对场所及技术要求较高,并不适用于日常生活减肥。中医减肥与上述方法相比具有较强的优点。世界各国的保健食品及药物减肥专家将目光聚焦于祖国的传统中医药宝库。
中医是我们祖国的文化瑰宝,历经几千年的洗礼而愈加兴盛,不仅呵护了人民的身体健康,也推动了世界医学的发展。传统中医认为肥胖是过食肥甘及久卧久坐、少劳等引起的以气虚痰湿偏盛为主,并伴有头晕乏力,少动气短等症状的一类病症。中医治疗肥胖以化湿祛痰、利水通腹、疏肝利胆、健脾温阳等作为施药原则。即泻下消导药:大黄、番泻叶等;祛痰化浊药:如半夏、白芥子等;活血化瘀药:如山楂、川穹等;利水渗湿药;荷叶、泽泻等。现代药理表明中医减肥主要是以减少摄食、抑制胃肠吸收、促进物质代谢、降血脂血糖、抗氧化等起作用。
我国有着丰富的中药资源,尤其是不少药食两用植物,诸如山楂、荷叶、茶叶等不仅有很好的去脂减肥作用,且食用安全,在临床上己得到广泛应用。因此将它们开发为有效的减肥食品,其市场潜力巨大。而探讨这类食用植物的减肥机制,是研制开发确实有效的减肥保健食品所必需的理论基础。目前市场上虽然己有一些利用食用中药配制的减肥胶囊和减肥茶,且市面减肥产品以减肥胶囊和袋泡茶居多,减肥颗粒冲剂则较少,214个减肥产品仅有18个是中药复方的颗粒冲剂,而且其中部分产品添加了左旋肉碱。与西药相比中药减肥副作用较小,为了达到减重效果,有些产品组方中添加了不少泻药,这类产品在短期内减重效果好,但是去除的大多是储留在机体内的水分,并没有起到真正减肥的作用,停药后反弹率高,且长期服用泻药会对身体造成损害,易发生肾结石和异常心理变化等疾病。随着传统自然药物逐渐受到大家的青睐,中药复方制剂将会有更加广泛的应用。但中药应用中仍然存在着农药残留高,重金属富集等问题,危害人类健康。
发明内容
本发明的目的在于提供一种脱重金属和农残的减肥药物及其制备方法和应用。
为了达到以上目的,本发明的技术方案如下:
一种减肥中药组合物,是由以下组分按重量份数制备而成:泽泻25-35份、黄芪20-40份、山楂15-25份、熟大黄10-20份、荷叶10-20份、姜黄10-20份。
在上述方案的基础上,所述减肥中药组合物,是由以下组分按重量份数制备而成:泽泻30份、黄芪30份、山楂20份、熟大黄15份、荷叶15份、姜黄15份。
一种减肥药物,是由以下组分按重量份数制备而成:泽泻25-35份、黄芪20-40份、山楂15-25份、熟大黄10-20份、荷叶10-20份、姜黄10-20份、壳聚糖5-12份。
在上述方案的基础上,所述的减肥药物,是由以下组分按重量份数制备而成:泽泻30份、黄芪30份、山楂20份、熟大黄15份、荷叶15份、姜黄15份、壳聚糖8份。
在上述方案的基础上,所述的减肥药物,还包括16-19份甘露醇和19-21份的木糖醇。
在上述方案的基础上,所述甘露醇为17.5份,所述木糖醇为20份。
一种减肥药物的剂型,所述剂型为汤剂、膏剂、颗粒剂、胶囊剂或片剂。
一种减肥的颗粒剂,是由以下组分按重量份数制备而成:泽泻25-35份、黄芪20-40份、山楂15-25份、熟大黄10-20份、荷叶10-20份、姜黄10-20份、壳聚糖5-12份、16-19份甘露醇、19-21份木糖醇。
在上述方案的基础上,所述减肥颗粒剂,是由以下组分按重量份数制备而成:泽泻30份、黄芪30份、山楂20份、熟大黄15份、荷叶15份、姜黄15份、壳聚糖8份、甘露醇17.5份、木糖醇20份。
在上述方案的基础上,所述减肥颗粒剂的制备方法,步骤如下:
1)将中药饮片置于pH为2.0-3.0的盐酸溶液中浸泡30-35分钟,然后捞出沥干清洗至中性;再置于pH为10.0-12.0的氢氧化钠溶液中浸泡30-35分钟,然后捞出沥干并清洗至中性;清洗后置于提取罐中,加入占投料重量7.9~8.1倍量纯化水,超声功率500W、发射频率为15KHz、脉冲周期频率为8次/s,清洗0.5h,排掉清洗水;
2)向清洗后的中药饮片中加入占投料重量7.9~8.1倍量纯化水,超声功率500W、发射频率为15KHz、脉冲周期频率为8次/s,75~85℃提取30分钟~40分钟,提取两次;离心分离得两次上清液,合并滤液,置于浓缩器中60℃,-0.9MPa浓缩至60℃的相对密度为1.05-1.10;
3)向上述预浓缩后的中药提取液中,加入经预处理的占提取液体积15%的除重金属用离子交换树脂,搅拌吸附30分钟;
4)将上述树脂吸附后的提取液,置于浓缩器中60℃,-0.9MPa浓缩至60℃的相对密度为1.25-1.35的浸膏;
5)向上述浸膏中加入甘露醇和壳聚糖,混合均匀后,将物料按2-5mm的厚度铺盘置于-20℃的冷冻干燥箱中,干燥至水分小于10%,然后用超微粉碎机对浸膏干粉进行粉碎,并过80目筛;
6)向上述浸膏干粉中,加入木糖醇,混合均匀后,并添加75份的体积分数为50%酒精进行造粒,造粒后过14-22目筛整粒,置于55℃烘箱中进行干燥,至水分<5%,即得所述颗粒剂。
本发明的保健法则结合了传统的中医理论和现代的西医理论,本方针对痰湿体质源于气虚阳弱,进而气滞、血瘀蒹夹为患的病机要点,治以益气健脾、温肾助阳、化痰祛湿、活血祛瘀立法。根据适宜人群证候,结合辩证保健的理法特点组方,保健法则为方中黄芪益气健脾,补气升阳,固表止汗,利水消肿;泽泻、荷叶分泄湿浊,使痰有外泄之通路;山楂活血散瘀,合姜黄、熟大黄活血祛瘀,水血同调,使血行湿化。诸药合用,既杜绝生痰之本源,又分消痰湿治气郁,标本兼顾,具有益气温阳、化痰祛湿、活血散瘀之功。除此之外,上述配方中壳聚糖作为膳食纤维,能包裹脂肪、延迟胃的排空,增加饱腹感,减少食物的摄入。综上所述,本方益气温阳,化痰祛湿,活血祛瘀。适用于肥胖及代谢综合征符合痰湿体质特征者。
本发明的有益效果
本发明的减肥药物,不含造成肝损伤的药物成分,且长时间服用具有护肝作用;减肥过程舒缓,促进肠道蠕动及排便,不会产生腹泻腹痛;减少食物摄入量,促进肠道脂肪的分解,抑制内脏周围脂肪的积聚和体重增加,减肥效果明显,本产品通过中药提取物的方剂配伍,达到协同增效作用,充分发挥了中药多层次多用途的特点。利用酸碱处理、超声清洗及树脂吸附等方法,提供了一种脱重金属和农残的浸膏制备方法及减肥颗粒剂的制备方法,克服了长期服用中药带来的副作用。采用超声提取的方式,将中药中有效成分最大程度的提取出来;运用低温浓缩、冷冻干燥等方式保护药物有效组分的活性,提高了药物有效成分的吸收率及生物利用度;采用颗粒剂的包装形式,方便携带,配方中添加低热值的木糖醇和甘露醇,既保证了口感又减少了热量的摄入,对于肥胖人群具有较好的减肥降脂作用。
具体实施方式
在本发明中所使用的术语,除非有另外说明,一般具有本领域普通技术人员通常理解的含义。
下面结合具体实施例,并参照数据进一步详细的描述本发明。以下实施例只是为了举例说明本发明,而非以任何方式限制本发明的范围。
实施例1
一种减肥的颗粒剂,是由以下组分按重量份数制备而成:
泽泻30份、黄芪30份、山楂20份、熟大黄15份、荷叶15份、姜黄15份、壳聚糖8份、甘露醇17.5份、木糖醇20份。
所述减肥的颗粒剂的制备方法,步骤如下:
1)将中药饮片置于pH为2.0-3.0的盐酸溶液中浸泡30-35分钟,然后捞出沥干清洗至中性;再置于pH为10.0-12.0的氢氧化钠溶液中浸泡30-35分钟,然后捞出沥干并清洗至中性;清洗后置于提取罐中,加入占投料重量7.9~8.1倍量纯化水,超声功率500W、发射频率为15KHz、脉冲周期频率为8次/s,清洗0.5h,排掉清洗水;
2)向清洗后的中药饮片中加入占投料重量7.9~8.1倍量纯化水,超声功率500W、发射频率为15KHz、脉冲周期频率为8次/s,75~85℃提取30分钟~40分钟,提取两次;离心分离得两次上清液,合并滤液,置于浓缩器中60℃,-0.9MPa浓缩至60℃的相对密度为1.05-1.10;
3)向上述预浓缩后的中药提取液中,加入经预处理的占提取液体积15%的除重金属用离子交换树脂,搅拌吸附30分钟;
4)将上述树脂吸附后的提取液,置于浓缩器中60℃,-0.9MPa浓缩至60℃的相对密度为1.25-1.35的浸膏;
5)向上述浸膏中加入17.5份甘露醇和8份壳聚糖,混合均匀后,将物料按2-5mm的厚度铺盘置于-20℃的冷冻干燥箱中,干燥至水分小于10%,然后用超微粉碎机对浸膏干粉进行粉碎,并过80目筛;
6)向上述浸膏干粉中,加入20份木糖醇,混合均匀后,并添加8份的体积分数为50%酒精进行造粒,造粒后过14-22目筛整粒,置于55℃烘箱中进行干燥,至水分<5%,即得所述颗粒剂。
实施例2
一种减肥的颗粒剂,是由以下组分按重量份数制备而成:
泽泻35份、黄芪25份、山楂25份、熟大黄18份、荷叶12份、姜黄18份、壳聚糖10份、甘露醇18.5份、木糖醇19份。
制备方法同实施例1。
实施例3
一种减肥的颗粒剂,是由以下组分按重量份数制备而成:
泽泻25份、黄芪20份、山楂15份、熟大黄10份、荷叶12份、姜黄11份、壳聚糖6份、甘露醇16份、木糖醇19份。
制备方法同实施例1。
实施例4
一种减肥的片剂的制备方法,步骤如下:
1)将实施例1-3方法制备的浸膏按2-5mm的厚度铺盘置于-20℃的冷冻干燥箱中,干燥至水分小于10%,然后用超微粉碎机对浸膏干粉进行粉碎,并过80目筛;
2)向上述浸膏干粉中添加1.4份的交联羧甲基纤维素钠,三维混合机混合均匀后,用3份的体积分数为50%酒精进行造粒,造粒后过14-22目筛整粒,置于55℃烘箱中进行干燥,至水分<5%。
3)向上述制备的颗粒中添加1.4份硬脂酸镁,三维混合机混合均匀后用高速压片机进行压片,即得所述片剂。
实施例5
一种减肥的胶囊剂的制备方法,步骤如下:
1)将实施例1-4方法制备的浸膏按2-5mm的厚度铺盘置于-20℃的冷冻干燥箱中,干燥至水分小于10%,然后用超微粉碎机对浸膏干粉进行粉碎,并过80目筛;
2)用3份的体积分数为50%酒精进行造粒,造粒后过14-22目筛整粒,置于55℃烘箱中进行干燥,至水分<5%。
3)向上述制备的颗粒中添加1.4份硬脂酸镁,三维混合机混合均匀后用全自动胶囊灌装机进行灌装,即得所述胶囊剂。
一、重金属和农残检测
1.1试验分组
1.1.1本发明实施例1方法制备的减肥颗粒,记为试验组;
1.1.2本发明实施例1方法不经酸碱清洗制备的减肥颗粒,记为对照组1;
1.1.3本发明实施例1方法不经超声清洗制备的减肥颗粒,记为对照组2;
1.1.4本发明实施例1方法不经离子交换树脂吸附制备的减肥颗粒,记为对照组3;
1.1.5市售减肥颗粒(某某牌美体减肥颗粒,主要成分为橘皮、黄芪、制何首乌、玄参、制大黄、天门冬酰苯丙氨酸甲酯),记为市售减肥药组。
1.2指标检测
1.2.1重金属含量检测
准确称量0.5g样品加入10mL混酸(HNO3:HClO4=4:1),封口静置过夜,然后在电炉上小心消化至冒出白色浓烟,消化液为无色透明或淡黄色近干时,加适量超纯水赶酸,冷却后,用超纯水定容至50mL,Agilent 7500a型电感耦合等离子体质谱仪测定重金属元素含量。每个样品取6个平行。
1.2.2农残含量检测
采用季思伟等方法(中药材农药多残留快速检测方法的研究,分析试验室,2010年,第29卷增刊,251-258页)检测本发明制备药物中农药的残留。
1.3检测结果
1.3.1重金属含量检测结果如表1所示:
表1减肥药中重金属含量检测结果(mg/kg)
组别 | 砷(As) | 铅(Pb) | 汞(Hg) | 镉(Cd) |
试验组 | 0.001 | 0.002 | 0.001 | 0.001 |
对照组1 | 0.008 | 0.010 | 0.009 | 0.010 |
对照组2 | 0.009 | 0.012 | 0.010 | 0.016 |
对照组3 | 0.013 | 0.026 | 0.018 | 0.018 |
市售减肥药组 | 0.040 | 0.090 | 0.090 | 0.080 |
由表1可知,本发明方法制备的减肥药物重金属砷、铅、汞、镉的含量显著低于对照组,而对照组中重金属砷、铅、汞、镉的含量显著低于市售减肥药物;这说明本发明的制备方法中酸碱处理、超声清洗及树脂吸附能够显著降低药物中的重金属残留,而且树脂吸附对重金属残留的影响较大。
1.3.2农残含量检测结果如表2所示:
表2减肥药中农残含量检测结果(mg/kg)
组别 | 试验组 | 对照组1 | 对照组2 | 对照组3 | 市售减肥药组 |
α-六六六 | 未检出 | 0.003 | 0.005 | 0.001 | 0.010 |
γ-六六六 | 未检出 | 未检出 | 未检出 | 未检出 | 0.003 |
o,p’-滴滴涕 | 未检出 | 0.001 | 0.001 | 未检出 | 0.003 |
p,p’-滴滴伊 | 未检出 | 未检出 | 未检出 | 未检出 | 0.002 |
p,p’-滴滴涕 | 未检出 | 未检出 | 未检出 | 未检出 | 0.001 |
氰戊菊酯 | 未检出 | 未检出 | 未检出 | 未检出 | 0.002 |
五氯硝基苯 | 未检出 | 未检出 | 未检出 | 未检出 | 0.001 |
六氯苯 | 未检出 | 未检出 | 0.003 | 未检出 | 0.005 |
七氯 | 未检出 | 未检出 | 0.001 | 未检出 | 0.003 |
艾氏剂 | 未检出 | 未检出 | 未检出 | 未检出 | 0.002 |
氯氰菊酯 | 未检出 | 未检出 | 未检出 | 未检出 | 0.001 |
杀扑磷 | 未检出 | 未检出 | 未检出 | 未检出 | 未检出 |
由表2可知,试验组制备的减肥药物未检出上述12种农残,而对照组2则检出α-六六六、o,p’-滴滴涕、六氯苯和七氯4种农残,对照组1检出α-六六六和o,p’-滴滴涕2种农残,市售减肥药则检出11种农残;这说明本发明的制备方法中酸碱处理、超声清洗及树脂吸附能够显著降低药物中的农残含量,而酸碱处理、超声清洗对农残含量的影响极大。
二、药效试验及安全性评价:
2.1试验分组
2.1.1实施例1的减肥颗粒剂
2.1.2实施例2的减肥颗粒剂
2.1.3实施例3的减肥颗粒剂
2.1.4实施例1的不含壳聚糖的减肥药物
2.1.5实施例1的不含壳聚糖、甘露醇和木糖醇的减肥药物
2.1.6市售减肥药(某某牌美体减肥颗粒,主要成分为橘皮、黄芪、制何首乌、玄参、制大黄、天门冬酰苯丙氨酸甲酯)。
2.2试验设计
按照卫生部《保健食品检验与评价技术规范》(2003版)中对应的实验方法进行下列各项评价实验。
试验动物:雄性SD大鼠,350只,体重48-55g,大鼠分笼饲养于19-24℃。明暗周期12h/12h,45%湿度的环境中,自由饮水,进食标准普通饲料。适应性饲养3d后,随机分为2组,正常对照组(30只)和造模组(320只),称量并记录各组大鼠的体重,正常对照组饲喂普通饲料,造模组饲喂高脂饲料,8周后,以超出对照组平均体重20%为肥胖标准,造模组中共有287只大鼠成为肥胖模型。
将造模组随机分为9组,每组30只。分为5个试验组和4个对照组;试验组1-3分别灌服本发明实施例1制备的减肥颗粒剂,灌服量分别为9g/Kg.BW(高剂量组)、3g/Kg.BW(中剂量组)、1.5g/Kg.BW(低剂量组);试验组4、5分别灌服本发明实施例2、3制备的减肥颗粒,灌服量为3g/Kg.BW(中剂量组);对照组1~3分别灌服2.1.4~2.1.6的减肥药物,灌服量为3g/Kg.BW(中剂量);对照组4不灌服任何药物;上述各组继续饲喂高脂饲料。正常对照组不灌服任何药物,继续饲喂普通饲料。
试验物料:
普通饲料:主要成分为玉米粉、高粱粉、小麦粉、麦麸、豆饼粉、豆粉、鱼粉、骨粉及少量的鱼肝油、酵母、矿物质等。
高脂饲料:含基础饲料76.5%、胆固醇3%、胆酸钠0.5%、酪蛋白10%、猪油10%。
各组大鼠自由生活及正常喂饲,每天观察大鼠摄食量、饮水量、精神状态、粪便干稀程度等,试验进行8周。
标本处理及数据采集:对给药8周的动物处死前称体重,用1%戊巴比妥钠腹腔注射麻醉大鼠,取附睾周围脂肪组织分别称取湿重,并测量各组大鼠体长(鼻尖到肛门的长度),计算Lee's指数[Lee's指数=(体重×1000)^(1/3)/体长(cm)]。
2.3试验结果:
2.3.1生活状态:试验结束时,正常组大鼠体态活泼,反应敏捷,食量、排泄物均正常。高脂组大鼠摄食量显著增多,活动减少,粪便时稀软。灌服本发明减肥颗粒的大鼠摄食量较正常组显著减少,饮水量、精神状态、排泄物基本正常;表明本发明制备的减肥颗粒安全,无不良适应症。
2.3.2减肥药物对大鼠体重、Lee’s指数、脂肪重量和腹泻率的影响如表3所示:
表3减肥颗粒对大鼠体重、Lee’s指数、脂肪重量的影响
组别 | 摄食量/g | 体重/g | 体长/cm | Lee’s指数 | 脂肪重量/g | 腹泻率/% |
试验组1 | 18.60±1.10Aa | 309.7±6.1Bb | 19.63±0.06a | 3.45±0.01Bb | 3.20±0.02De | 0.03 |
试验组2 | 18.17±1.06Aa | 313.3±3.8Bb | 19.59±0.09a | 3.47±0.04Bb | 3.22±0.07De | 0 |
试验组3 | 18.29±1.24Aa | 343.5±5.0Cc | 19.60±0.05a | 3.57±0.03Cc | 3.64±0.05Cc | 0 |
试验组4 | 18.42±1.02Aa | 317.1±7.4Bb | 19.52±0.10a | 3.49±0.02Bb | 3.23±0.04De | 0 |
试验组5 | 18.65±0.98Aa | 321.4±4.3Bb | 19.69±0.13a | 3.48±0.05Bb | 3.25±0.01De | 0 |
对照组1 | 19.58±0.68Ab | 345.0±6.2Ccd | 19.55±0.07a | 3.59±0.04Cc | 3.43±0.06CDd | 0 |
对照组2 | 20.64±0.92Ac | 348.2±4.7Ccd | 19.48±0.12a | 3.61±0.02Cc | 3.45±0.04CDd | 0 |
对照组3 | 20.13±0.45Ac | 352.7±7.6Cd | 19.57±0.06a | 3.61±0.04Cc | 3.66±0.08Cc | 0.12 |
对照组4 | 23.87±1.84Bd | 378.3±8.0De | 19.78±0.15a | 3.66±0.03Cd | 3.93±0.08Bb | 0 |
正常组 | 21.15±1.46Ac | 286.7±12.7Aa | 19.63±0.08a | 3.36±0.06Aa | 2.98±0.05Aa | 0 |
注:同列肩标字母相同表示差异不显著(P>0.05),肩标不同小写字母表示差异显著(P<0.05),肩标不同大写字母表示差异极显著(P<0.01)。
由表3可见,试验组1~5的摄食量极显著低于对照组4的摄食量,且显著低于对照组1、2、3和正常组的摄食量,对照组1显著低于对照组2、3和正常组的摄食量,试验组1~5之间无显著差异;试验组1、2、4、5的体重极显著低于试验组3和对照组1、2、3、4,试验组3和对照组3极显著低于对照组4,且试验组3显著低于对照组3,对照组1、2与试验组3和对照组3之间无显著差异,正常组的体重极显著低于其他各组;各组大鼠的体长无显著差异;试验组1、2、4、5的Lee’s指数极显著低于试验组3和对照组1、2、3、4,试验组3和对照组1、2、3显著低于对照组4,正常组的Lee’s指数极显著低于其他各组;对照组4的脂肪重量极显著高于其他各组,正常组的脂肪重量极显著低于其他各组,试验组1、2、4、5的脂肪重量极显著低于试验组3和对照组3,试验组1、2显著低于对照组1、2的脂肪重量,对照组1、2的脂肪重量显著低于试验组3和对照组3;除试验组1和对照组3有轻微的腹泻外,其他各组均无腹泻产生,且试验组1的腹泻率显著低于对照组3。
上述结果说明:服用本发明的减肥颗粒能够显著降低食物的摄入量、体重、Lee’s指数和脂肪重量;壳聚糖、甘露糖和木糖醇的添加能够影响摄食量、体重、Lee’s指数和脂肪重量;本发明减肥颗粒的使用剂量对摄食量的影响不大,对体重、Lee’s指数和脂肪重量有显著的影响,服用低剂量本法明减肥颗粒大鼠的体重、Lee’s指数和脂肪重量显著高于中高剂量组,中剂量和高剂量组间无显著差异,但服用高剂量的减肥颗粒能够产生轻微的腹泻,因此,为达到较好的减肥效果而不对身体造成伤害,建议服用中剂量。
上述实施方案为本发明最佳的实施方案,但本发明的实施方案并不受上述实施方案的限制,其他的任何不违背本发明原理的条件下,可以通过改变参数的形式所产生的实施例,都包含于本发明的保护范围之内。
Claims (10)
1.一种减肥中药组合物,其特征在于:是由以下组分按重量份数制备而成:泽泻25-35份、黄芪20-40份、山楂15-25份、熟大黄10-20份、荷叶10-20份、姜黄10-20份。
2.根据权利要求1所述减肥中药组合物,其特征在于:是由以下组分按重量份数制备而成:泽泻30份、黄芪30份、山楂20份、熟大黄15份、荷叶15份、姜黄15份。
3.一种减肥药物,其特征在于:是由以下组分按重量份数制备而成:泽泻25-35份、黄芪20-40份、山楂15-25份、熟大黄10-20份、荷叶10-20份、姜黄10-20份、壳聚糖5-12份。
4.根据权利要求3所述的减肥药物,其特征在于:是由以下组分按重量份数制备而成:泽泻30份、黄芪30份、山楂20份、熟大黄15份、荷叶15份、姜黄15份、壳聚糖8份。
5.根据权利要求3所述的减肥药物,其特征在于:还包括16-19份甘露醇和19-21份的木糖醇。
6.根据权利要求5所述的减肥药物,其特征在于:所述甘露醇为17.5份,所述木糖醇为20份。
7.一种减肥药物的剂型,其特征在于:所述剂型为汤剂、膏剂、颗粒剂、胶囊剂或片剂。
8.一种减肥的颗粒剂,其特征在于:是由以下组分按重量份数制备而成:泽泻25-35份、黄芪20-40份、山楂15-25份、熟大黄10-20份、荷叶10-20份、姜黄10-20份、壳聚糖5-12份、甘露醇16-19份、木糖醇19-21份。
9.根据权利要求8所述减肥颗粒剂,其特征在于:是由以下组分按重量份数制备而成:泽泻30份、黄芪30份、山楂20份、熟大黄15份、荷叶15份、姜黄15份、壳聚糖8份、甘露醇17.5份、木糖醇20份。
10.根据权利要求8或9所述减肥颗粒剂的制备方法,其特征在于:步骤如下:
1)将中药饮片置于pH为2.0-3.0的盐酸溶液中浸泡30-35分钟,然后捞出沥干清洗至中性;再置于pH为10.0-12.0的氢氧化钠溶液中浸泡30-35分钟,然后捞出沥干并清洗至中性;清洗后置于提取罐中,加入占投料重量7.9~8.1倍量纯化水,超声功率500W、发射频率为15KHz、脉冲周期频率为8次/s,清洗0.5h,排掉清洗水;
2)向清洗后的中药饮片中加入占投料重量7.9~8.1倍量纯化水,超声功率500W、发射频率为15KHz、脉冲周期频率为8次/s,75~85℃提取30分钟~40分钟,提取两次;离心分离得两次上清液,合并滤液,置于浓缩器中60℃,-0.9MPa浓缩至60℃的相对密度为1.05-1.10;
3)向上述预浓缩后的中药提取液中,加入经预处理的占提取液体积15%的除重金属用离子交换树脂,搅拌吸附30分钟;
4)将上述树脂吸附后的提取液,置于浓缩器中60℃,-0.9MPa浓缩至60℃的相对密度为1.25-1.35的浸膏;
5)向上述浸膏中加入甘露醇和壳聚糖,混合均匀后,将物料按2-5mm的厚度铺盘置于-20℃的冷冻干燥箱中,干燥至水分小于10%,然后用超微粉碎机对浸膏干粉进行粉碎,并过80目筛;
6)向上述浸膏干粉中,加入木糖醇,混合均匀后,并添加75份的体积分数为50%酒精进行造粒,造粒后过14-22目筛整粒,置于55℃烘箱中进行干燥,至水分<5%,即得所述颗粒剂。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710692953.2A CN107375847A (zh) | 2017-08-14 | 2017-08-14 | 一种减肥药物、其制备方法及应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710692953.2A CN107375847A (zh) | 2017-08-14 | 2017-08-14 | 一种减肥药物、其制备方法及应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN107375847A true CN107375847A (zh) | 2017-11-24 |
Family
ID=60355853
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710692953.2A Pending CN107375847A (zh) | 2017-08-14 | 2017-08-14 | 一种减肥药物、其制备方法及应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107375847A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108236646A (zh) * | 2018-02-06 | 2018-07-03 | 贺建华 | 减肥水凝胶贴剂及其制备方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010054470A1 (en) * | 2008-11-17 | 2010-05-20 | Northern Innovations And Formulations Corp. | Pumpkin and rose hips weight loss composition |
CN102743504A (zh) * | 2012-07-25 | 2012-10-24 | 中国热带农业科学院热带生物技术研究所 | 一种减肥降脂的中药组合物、制剂及食品 |
CN103652514A (zh) * | 2013-12-12 | 2014-03-26 | 无锡市善源生物科技有限公司 | 一种降低大米及其制品重金属含量的方法 |
-
2017
- 2017-08-14 CN CN201710692953.2A patent/CN107375847A/zh active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010054470A1 (en) * | 2008-11-17 | 2010-05-20 | Northern Innovations And Formulations Corp. | Pumpkin and rose hips weight loss composition |
CN102743504A (zh) * | 2012-07-25 | 2012-10-24 | 中国热带农业科学院热带生物技术研究所 | 一种减肥降脂的中药组合物、制剂及食品 |
CN103652514A (zh) * | 2013-12-12 | 2014-03-26 | 无锡市善源生物科技有限公司 | 一种降低大米及其制品重金属含量的方法 |
Non-Patent Citations (7)
Title |
---|
张炳盛等: "《中药药剂学》", 28 February 2013, 中国医药科技出版社 * |
杨玉玲: "超声波技术在农药残留研究中的应用", 《农药研究与应用》 * |
王丽清等: "活血利湿法治疗儿童单纯性肥胖并高脂血症21例", 《新中医》 * |
白新鹏: "《功能性食品设计与评价》", 30 June 2009, 中国计量出版社 * |
蒋仙玮等: "脱除重金属的技术方法", 《食品工业科技》 * |
邓舜扬: "《功能性食品与保健》", 31 August 2006, 科学技术文献出版社 * |
陈小刚: "《常用中草药临床新用》", 31 March 2005, 广东科技出版社 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108236646A (zh) * | 2018-02-06 | 2018-07-03 | 贺建华 | 减肥水凝胶贴剂及其制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101878833B (zh) | 一种排毒美颜茶及其制备方法 | |
CN103535596A (zh) | 一种富含膳食纤维保健粉及其制备方法 | |
CN104814086A (zh) | 一种基于甘薯的功能性糕点及其制备方法 | |
CN102697843B (zh) | 一种清肠通便排毒养颜保健品及其制备方法 | |
CN102640825B (zh) | 一种调节血脂的食品降脂茶冲剂 | |
CN107375847A (zh) | 一种减肥药物、其制备方法及应用 | |
CN108721431A (zh) | 一种排重金属的中药组合物及其应用 | |
CN102526639B (zh) | 治疗高血脂症的中药组合物及其制备方法 | |
KR101446277B1 (ko) | 천연약재를 이용한 조성물 및 이의 제조방법 | |
CN1143516A (zh) | 均衡营养康复素及其制备方法 | |
CN107114514A (zh) | 一种清热降脂减肥茶及其制备方法 | |
CN104288566B (zh) | 降胆固醇和/或降血脂的中药组合物及其制备方法和应用 | |
KR101484840B1 (ko) | 한약농축액과 한약분말을 이용한 한방농축환 제조방법 | |
CN100496590C (zh) | 治疗脂肪肝的药物及其制备方法 | |
CN103520652B (zh) | 一种治疗肝癌的中药组合物 | |
CN102743442A (zh) | 一种改善胃肠功能的中药组合物及制备方法 | |
CN1115159C (zh) | 一种含紫丹参的药物组合物及其制备方法和应用 | |
CN1557383A (zh) | 双蚁祛湿通络胶囊 | |
CN110151940A (zh) | 一种健脾温肾的中药组合物及其制备方法 | |
CN105169187B (zh) | 一种组合物及其应用,其制备方法以及含有该组合物的药物、食品 | |
CN101524505A (zh) | 一种治疗腹泻的中药组合物 | |
CN107668713A (zh) | 纤体散制备方法 | |
CN103330245A (zh) | 血耳四红汤 | |
CN108543054A (zh) | 一种补钙胶囊及其制备方法 | |
CN108740722A (zh) | 一种养生保健功效食品及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20171124 |
|
RJ01 | Rejection of invention patent application after publication |